Wenqiang Li

Wenqiang Li

Auto-generated profile, based on publicly available information

Wenqiang Li

Department of General Surgery, Aerospace Center Hospital

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2025 in Autophagy
Verified
Journal Article
Open access
GXGuoshuai Xu
Guoshuai Xu
QZQinghong Zhang
Qinghong Zhang
RCRenjia Cheng
Renjia Cheng
Jun QuJun Qu
Jun Qu
WLWenqiang Li
Wenqiang Li
Macropinocytosis is a nonselective form of endocytosis that allows cancer cells to largely take up the extracellular fluid and its contents, including nutrients, growth factors, etc. We first elaborate meticulously on the process of macropinocytosis. Only by thoroughly understanding this entire process can we devise targeted strategies against it. We then focus on the central role of the MTOR (mechanistic target of rapamycin kinase) complex 1 (MTORC1) in regulating macropinocytosis, highlighting its significance as a key signaling hub where various pathways converge to control nutrient uptake and metabolic processes. The article covers a comprehensive analysis of the literature on the molecular mechanisms governing macropinocytosis, including the initiation, maturation, and recycling of macropinosomes, with an emphasis on how these processes are hijacked by cancer cells to sustain their growth. Key discussions include the potential therapeutic strategies targeting macropinocytosis, such as enhancing drug delivery via this pathway, inhibiting macropinocytosis to starve cancer cells, blocking the degradation and recycling of macropinosomes, and inducing methuosis - a form of cell death triggered by excessive macropinocytosis. Targeting macropinocytosis represents a novel and innovative approach that could significantly advance the treatment of cancers that rely on this pathway for survival. Through continuous research and innovation, we look forward to developing more effective and safer anti-cancer therapies that will bring new hope to patients.Abbreviation: AMPK: AMP-activated protein kinase; ASOs: antisense oligonucleotides; CAD: carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase; DC: dendritic cell; EGF: epidermal growth factor; EGFR: epidermal growth factor receptor; ERBB2: erb-b2 receptor tyrosine kinase 2; ESCRT: endosomal sorting complex required for transport; GAP: GTPase-activating protein; GEF: guanine nucleotide exchange factor; GRB2: growth factor receptor bound protein 2; LPP: lipopolyplex; MTOR: mechanistic target of rapamycin kinase; MTORC1: mechanistic target of rapamycin kinase complex 1; MTORC2: mechanistic target of rapamycin kinase complex 2; NSCLC: non-small cell lung cancer; PADC: pancreatic ductal adenocarcinoma; PDPK1: 3-phosphoinositide dependent protein kinase 1; PI3K: phosphoinositide 3-kinase; PIK3C3: phosphatidylinositol 3-kinase catalytic subunit type 3; PtdIns(3,4,5)P3: phosphatidylinositol-(3,4,5)-trisphosphate; PtdIns(4,5)P2: phosphatidylinositol-(4,5)-bisphosphate; PTT: photothermal therapies; RAC1: Rac family small GTPase 1; RPS6: ribosomal protein S6; RPS6KB1: ribosomal protein S6 kinase B1; RTKs: receptor tyrosine kinases; SREBF: sterol regulatory element binding transcription factor; TFEB: transcription factor EB; TNBC: triple-negative breast cancer; TSC2: TSC complex subunit 2; ULK1: unc-51 like autophagy activating kinase 1; UPS: ubiquitin-proteasome system.

16 March 2026 in Cancer Biology & Therapy
Verified
Journal Article
Open access
GXGuoshuai Xu
Guoshuai Xu
NYNan Yao
Nan Yao
RCRenjia Cheng
Renjia Cheng
LYLin Yang
Lin Yang
FHFuzhou Han
Fuzhou Han
WLWenqiang Li
Wenqiang Li
Recent research has highlighted the critical role of copper metabolism and a novel form of copper-dependent cell death, termed cuproptosis, in the progression and treatment of these cancers. Copper, an essential trace element, plays a crucial role in various cellular processes, including mitochondrial function, antioxidant defense, and angiogenesis. However, the dysregulation of copper homeostasis in cancer cells can exacerbate genomic instability, promote angiogenesis, and reshape the immune microenvironment, thereby driving tumor progression. This review systematically explores the mechanisms of copper homeostasis and cuproptosis in digestive system cancers. We also explore innovative strategies for overcoming drug resistance and reshaping immune responses through copper chelators, copper ionophores, and nanomedicines that induce cuproptosis. By integrating basic research with clinical evidence, this review aims to provide a scientific perspective on understanding the biological significance of cuproptosis and developing new anticancer strategies, while also stimulating in-depth thinking on the intersection of metabolic intervention and cell death.

1 February 2026 in Digital Health
Verified
Journal Article
Open access
NYNan Yao
Nan Yao
GXGuoshuai Xu
Guoshuai Xu
NDNing Duan
Ning Duan
FHFuzhou Han
Fuzhou Han
WLWenqiang Li
Wenqiang Li
JQJun Qu
Jun Qu
Background: Multimodal artificial intelligence (AI) and foundation models are being applied to clinical evidence generation, but technical performance does not establish clinical utility or causal validity. Objective: To critically examine evidence for AI-assisted trial workflows and propose practical safeguards for real-world evidence generation. Methods: This narrative review combines empirical, methodological and governance sources. Original screening was performed by one author; historical records were unavailable. An AI-assisted PubMed and Europe PMC preprint update on 12 September 2026 covered 2016–2026 and yielded 8,172 deduplicated records. Purposive evidence selection, rather than exhaustive screening, informed nine illustrative empirical comparisons. A structured domain-based critique informed interpretation; no validated risk-of-bias tool or meta-analysis was used. Results: Evidence ranges from technical benchmarks to prospective evaluations. A heart-failure recruitment randomized trial demonstrated faster eligibility determination with LLM assistance; enrollment was exploratory. Prospective oncology matching studies assessed different outcomes and do not establish general enrollment or equity benefits. Multimodal endpoint results based on cross-validation require independent clinical validation. The framework links investigator-defined target trials and variable roles to source verification, causal safeguards, human review, prospective evaluation and change control. Proposed gates address false exclusions, endpoint timing, missing modalities, external comparators and privacy. Conclusions: AI can support selected research workflows, but performance must be interpreted within the task, study design and clinical setting. The framework is an unvalidated conceptual synthesis. Single-author historical selection, non-exhaustive AI-assisted updating, heterogeneous evidence and changing governance limit completeness and generalizability.